Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Acute Myelogenous Leukemia Clinical Trial

Official title:

A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04709458
• Other study ID #: TBX-2400-001
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: September 1, 2022
• Est. completion date: October 28, 2024

Study information

• Verified date: May 2022
• Source: Taiga Biotechnologies, Inc.
• Contact: Vivienne Margolis, B.Sc
• Phone: +972-4639634
• Email: vmargolis[@]taigabiotech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study of allogeneic stem cell transplantation with TBX-2400 in adult subjects with Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF).

The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way.

This study has two goals. The first goal is to find out if transplant with TBX-2400 is safe. The second goal is to find out what effects TBX-2400 stem cells have on time to engraftment in adult subjects with AML or MF.

The study hypothesis is that TBX-2400 cells will shorten the time to immune reconstitution after transplant.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: October 28, 2024
• Est. primary completion date: August 28, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. For crAML: AML with =5% blasts (either by morphology or by multi-parameter flow cytometry [MFC]) in a marrow aspirate obtained within 21 days of enrollment in the trial, and following the administration of at least two prior courses of chemotherapy;

2. For MF: primary MF or MF that has progressed from a myeloproliferative disease. Dynamic International Prognostic Scoring System (DIPSS)-plus to be utilized to support the inclusion of MF subjects at screening;

3. Subject undergoing allogeneic stem cell transplantation on the decision of transplanting physician;

4. Signed informed consent of donor and recipient;

5. Subjects of = 18 years of age (no upper age limit);

6. Donor agrees to donate bone marrow-derived or mobilized peripheral blood stem cells;

7. Subjects with Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2;

8. Adequate pulmonary function with Diffusing Capacity for Carbon Monoxide (DLCO) > 50;

9. Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception (e.g. sterilization, hormone implants, hormone injections, intrauterine devices, or vasectomized partner with combined use of condom and/or birth control pills) from screening until 6 months after TBX-2400 transplantation;

10. Able to adhere to all trial treatments and procedures.

Exclusion Criteria:

1. Previous stem cell transplantation;

2. For MF: Blasts > 10% in a marrow aspirate obtained within 30 days of screening;

3. Renal function: serum creatinine > 1.5 x Upper Limit of Normal (ULN);

4. Hepatic function: impaired synthetic function as indicated by a serum fibrinogen below the normal limit. Aspartate transaminase/alanine transaminase (AST/ALT) > 3.0 x ULN. Bilirubin, > 1.5 x ULN;

5. Cardiac function: ejection fraction < 45% as determined by echocardiography;

6. Prior malignancy active within previous three years - except for locally curable cancers such as cutaneous basal or squamous cell cancer, superficial bladder cancer, carcinoma in situ of cervix or breast, or carcinoma in situ of the prostate;

7. Positive pregnancy test or breastfeeding for women of childbearing age;

8. Serologic evidence of chronic Hepatitis B virus infection or Hepatitis C exposure;

9. Known history of positive test for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS);

10. Hypersensitivity to any trial medication (including the preparative regimen, TBX-2400 treatment and any prophylaxis or other medication planned);

11. Presence of a serious or uncontrolled medical disorder that, in the opinion of the Investigator, may increase the risk associated with trial participation or trial drug administration, impair the ability of the participant to receive protocol therapy, or interfere with interpretation of trial results.

Related Conditions & MeSH terms

• Acute Myelogenous Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelofibrosis
• Primary Myelofibrosis

Intervention

Biological:
• TBX-2400
Hematopoietic stem cells transplantation

Locations

Country	Name	City	State
Croatia	University Hospital Centre Zagreb	Zagreb
Italy	Fondazione Policlinico Universitario Agostino Gemelli	Roma

Sponsors (1)

Lead Sponsor	Collaborator
Taiga Biotechnologies, Inc.

Countries where clinical trial is conducted

Croatia,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events according to NCI-CTCAE Version 5.0	Adverse events from subject reporting or other assessments	Two years
Primary	Transplant engraftment	Assessment of transplant engraftment will include absolute neutrophil count, untransfused platelet count and donor chimerism	1 year
Secondary	Immune reconstitution as measured by CD3+ cell count	Immune reconstitution as measured by CD3+ cell count > 300/µL	Up to Day 360
Secondary	Immunoglobulin (IgA) levels		Up to Day 360
Secondary	Immunoglobulin (IgM) levels		Up to Day 360
Secondary	T-cell Engraftment	CD45 RA versus RO at 3, 6, 9 and 12 months	Up to Day 360
Secondary	Disease-free survival		Two years
Secondary	Incidence of secondary graft failure		Two years
Secondary	Transplant-Related Mortality (TRM)		100 Days
Secondary	Quality of life using the World Health Organisation Five Wellbeing Index	QoL assessed at 3, 6, 9 and 12 months (World Health Organization [WHO] Five Wellbeing Index).	Up to day 360